tbuckley/cabot-search huggingface dataset:
Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation
Authors: Bo Xiao, Zhan Zhang, Emilie Viennois, Yuejun Kang, Mingzhen Zhang, Moon Kwon Han, Jiucun Chen, Didier Merlin
Journal: Theranostics (2016)

Combination therapy is an emerging strategy that is under intensive preclinical investigation for the treatment of various diseases. CD98 is highly overexpressed on the surfaces of epithelial cells and macrophages in the colon tissue with ulcerative colitis (UC), which is usually associated with mucosal damage and inflammation. We previously proved that CD98 siRNA (siCD98)-induced down-regulation of CD98 in colitis tissue decreased the severity of UC to a certain extent. In an effort to further improve the therapeutic efficacy, we aim to simultaneously deliver siCD98 in combination with a potent anti-inflammatory agent, curcumin (CUR), using hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs). The resultant spherical HA-siCD98/CUR-NPs are featured by a desirable particle size (∼246 nm) and slightly negative zeta potential (∼-14 mV). The NPs functionalized with HA are able to guide the co-delivery of drugs to the targeted cells related to UC therapy (colonic epithelial cells and macrophages). Compared to either siCD98- or CUR-based monotherapy, co-delivery of siCD98 and CUR by HA-functionalized NPs can exert combinational effects against UC by protecting the mucosal layer and alleviating inflammation both in vitro and in vivo. This study shows the promising capability of the co-delivered siCD98 and CUR for boosting the conventional monotherapy via this novel nanotherapeutic agent, which offers a structurally simple platform for orally administered delivery of drugs to target cells in UC therapy.
Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.
Authors: Michael J. Dugan, Luke P. Akard, James M. Thompson, Auayporn Nademanee, Richard T. Maziarz, William I. Bensinger, Jane Liesveld, Karin Badel, Christine Dehner, Colleen Gibney, Gary Calandra, Jan Jansen
Journal: Blood (2004)
PWE-029 Utility of Measurement Anti TNF Drug and Anti Drug Antibody Levels in A Cohort of Patients with Crohn’s Disease: How Does it Affect Clinical Practice?: Abstract PWE-029 Table 1
Authors: S Laird, L Caulfield, LA Smith, JW Winter, DR Gaya, AJ Morris
Journal: Gut (2016)

<h3>Introduction</h3> It has been recognised that the measurement of anti-TNF drug concentrations and detection of anti drug antibodies may be useful in aiding decision making and therefore optimising clinical outcomes in patients on anti-TNF drugs in whom there is incomplete clinical response or loss of drug therapy.<sup>1</sup> <h3>Methods</h3> A total of 45 Crohn’s patients attending our tertiary referral IBD clinic had anti TNF drug concentrations and antidrug antibodies levels measured. The indications for testing were incomplete response or loss of response during therapy. We measured drug levels and Anti Drug Antibody levels using the ELISA assay (Immunodiagnostik). Reference ranges for Infliximab &gt;2.0 ug/ml therapeutic and Adalimumab &gt;5.0 ug/ml therapeutic. Total drug antibody levels &gt;10 AU/ml positive. <h3>Results</h3> We present the patient demographics in <b>Table 1.</b> <h3>Drug and ADA levels</h3> 44% (n = 20) had therapeutic levels and negative antibodies, 18% (n = 8) had therapeutic levels and positive antibodies, 22% (n = 10) had sub-therapeutic levels and negative antibodies and 16% (n = 7) had sub-therapeutic levels and positive antibodies. <h3>Impact of results</h3> meaurement of drug and ADA led to change in management in 28/45 (62%) patients. 6 (13%) patients switched therapy,17 (38%) had dose escalation,17 (38%) no treatment change,5 (11%)other outcome. <h3>Conclusion</h3> Measurement of anti-TNF drug concentrations and antibody status in our patients on Anti TNF resulted in change of management in 28/45 (62%) patients. In the 17 patients with dose escalation in whom outcome was assessed 13 (76%) patients have responded. Measurement of drug concentration and antibody status presents an possible option in the management of patients on anti-TNF who present with loss of response or incomplete response of treatment <h3>Reference</h3> 1 Vande Casteele N, <i>et al.</i> The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. <i>GUT</i> 2015 Oct;<b>64</b>(10):1539–45. <h3>Disclosure of Interest</h3> S. Laird: None Declared, L. Caulfield: None Declared, L. Smith Conflict with: cook, boston and allergan, almirall, J. Winter Conflict with: almirall, reckitt-Benckisaer, ferring, shire, D. Gaya: None Declared, A. Morris Conflict with: Falk,Vifor
Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Rapidly Relapsing Hodgkin’s Disease.
Authors: Brian Bolwell, Brad Pohlman, Ronald Sobecks, Steven Andresen, Lisa Rybicki, Stacey Brown, Elizabeth Kuczkowski, Jennifer Bates, Laura Bernhard, Kelly Cherni, Janet Baker, Matt Kalaycio
Journal: Blood (2005)
Effect of alterations in apoptotic pathway on development of metabolic syndrome in patients with psoriasis vulgaris
Authors: S. Korkmaz, H. Korkmaz
Journal: British Journal of Dermatology (2016)

An increase in the incidence of metabolic syndrome (MetS) has been identified in patients with psoriasis. To evaluate the role of changes in expression of apoptosis activators [B‐cell lymphoma (Bcl)‐2‐like protein 4 (BAX), cytochrome c (cytC) and caspase‐3 (CASP3)] and apoptosis inhibitors [Bcl‐2, survivin, cyclin D1 (CCND1), superoxide dismutase (SOD), catalase 3 (CAT), glutathione synthetase (GS), heat shock protein (Hsp)27, Hsp60, Hsp70 and Hsp90] on development of MetS in patients with psoriasis vulgaris. Fifty patients with psoriasis were enrolled; 25 had MetS. Twenty‐five healthy people and 25 people with only MetS were included as a control group. Serum fasting blood glucose, urea, creatinine, total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides, thyroid‐stimulating hormone, fraction of thyroxine, fasting insulin and highly sensitive C‐reactive protein levels were measured. Expression of BAX, cytC, CASP3, Bcl‐2, survivin, CCND1, SOD, CAT, GS, and Hsp27, Hsp60, Hsp70 and Hsp90 were measured in peripheral blood. Clinical activation of patients with psoriasis was calculated using Psoriasis Area and Severity Index scores. In patients with MetS there was an increase in expression of genes for cytC, survivin and Hsp27, Hsp60 and Hsp90, and a decrease in expression of CCND1. Furthermore, expression levels of CCND1 were identified to be an independent risk factor for MetS development in patients with psoriasis. The increase in expression of survivin and Hsp27, Hsp60 and Hsp90, and the decrease in CCND1 expression may be important mechanisms in the development of MetS in patients with psoriasis.
Oxymetholone Therapy of Fanconi Anemia Induces Hematopoietic Stem Cell Cycling By Suppressing Osteopontin Transcription
Authors: Qingshuo Zhang, Eric Benedetti, Matthew Deater, Kathryn Schubert, Angela Major, Carl Pelz, Soren Impey, Laura Marquez-Loza, Keaney Rathbun, Shigeaki Kato, Grover C. Bagby, Markus Grompe
Journal: Blood (2014)
Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial
Authors: Amrita Krishnan, Marcelo C Pasquini, Marian Ewell, Edward A. Stadtmauer, Edwin P Alyea, Joseph H. Antin, Raymond L. Comenzo, Stacey Goodman, Parameswaran Hari, Robert Negrin, Muzaffar H. Qazilbash, Scott D Rowley, Firoozeh Sahebi, George Somlo, David H. Vesole, Dan T. Vogl, Daniel J. Weisdorf, Nancy Geller, Mary M. Horowitz, Sergio Giralt, David G. Maloney
Journal: Blood (2010)
Efficient Engraftment and Disease Replication of Myelodysplastic Syndromes Using a Novel Humanized Mice Model
Authors: Yuanbin Song, Ashley Taylor, Anthony Rongvaux, Tingting Jiang, Nikolai A. Podoltsev, Mina Xu, Natalia Neparidze, Richard Torres, Lisa M Barbarotta, Kunthavai Balasubramanian, Karin E Finberg, Yuval Kluger, Richard Flavell, Stephanie Halene
Journal: Blood (2015)
PTU-041 Impact of Time to Endoscopy On Mortality in Patients with Non Variceal Upper GI Bleed
Authors: SAA Gardezi, C Tibbatts, A Foliaki, L Chase, H Javaid
Journal: Gut (2016)

<h3>Introduction</h3> Acute upper GI Bleed (AUGIB) is one of the most common presentations in UK hospitals and is associated with significant morbidity and mortality. Current guidelines recommend early endoscopic intervention (i.e. Within 24 hours) for patients presenting with UGIB.<sup>1</sup> Early endoscopy can be beneficial in achieving hemostasis more quickly &amp; decreasing need for transfusions.<sup>2</sup> However aggressive resuscitation before rushing towards an endoscopy has its own importance as Inadequate early resuscitation is believed to be a major factor in the persistently high mortality rate in patients with UGIB.<sup>3</sup> <h3>Methods</h3> We conducted a retrospective study of 696 patients who were admitted to Cardiff and Vale university health board &amp; subsequently treated in endoscopy unit for non variceal upper GI bleed between September 2010 and September 2013. Patients were divided into 3 groups depending upon the time to scope from admission (Within 6 hours, 6–24 hours and more than 24 hours). <h3>Results</h3> Our study found that very early endoscopy (i.e. &lt;6 hours) compared to rapid endoscopy (6–24 hours), did not improve outcome and in fact had a significantly worse mortality rate of 16.67% vs 4.62% . Though it can be argued that patients who had a very early endoscopy were more unwell comparatively. When we compared patients in high risk group only i.e. GBS (Glasgow Blatchford &gt;10); results were identical. <h3>Conclusion</h3> Our study reinforced the importance of access to rapid endoscopic intervention within 24 hours, but did not demonstrate the need for very early gastroscopy. This was likely due to the fact that organising very early endoscopy within 6 h would slow intensive resuscitative efforts leading to worse outcome. <h3>References</h3> 1 https://www.nice.org.uk/Guidance/CG141 2 Cooper GS, <i>et al</i>. Early endoscopy in upper gastrointestinal haemorrhage. <i>Gastrointest Endosc</i> 1999;<b>49</b>:145–52. 3 Baradarian R, Ramdhaney S, Chapalamadugu R, <i>et al</i>. Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. <i>Am J Gastroenterol</i> 2004;<b>99</b>:619–22. <h3>Disclosure of Interest</h3> None Declared
Existing and Emerging Payment and Delivery Reforms in Cardiology
Authors: Steven A. Farmer, Margaret L. Darling, Meaghan George, Paul N. Casale, Eileen Hagan, Mark B. McClellan
Journal: JAMA Cardiology (2016)

<h3>Importance</h3> Recent health care reforms aim to increase patient access, reduce costs, and improve health care quality as payers turn to payment reform for greater value. Cardiologists need to understand emerging payment models to succeed in the evolving payment landscape. We review existing payment and delivery reforms that affect cardiologists, present 4 emerging examples, and consider their implications for clinical practice. <h3>Observations</h3> Public and commercial payers have recently implemented payment reforms and new models are evolving. Most cardiology models are modified fee-for-service or address procedural or episodic care, but population models are also emerging. Although there is widespread agreement that payment reform is needed, existing programs have significant limitations and the adoption of new programs has been slow. New payment reforms address some of these problems, but many details remain undefined. <h3>Conclusions and Relevance</h3> Early payment reforms were voluntary and cardiologists' participation is variable. However, conventional fee-for-service will become less viable, and enrollment in new payment models will be unavoidable. Early participation in new payment models will allow clinicians to develop expertise in new care pathways during a period of relatively lower risk.
Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).
Authors: Athanasios Anagnostopoulos, Dimitra Gika, Argiris Symeonidis, Konstantinos Zervas, Anastasia Pouli, Panagiotis Repoussis, Vassiliki Grigoraki, Nikolaos Anagnostopoulos, Alice G. Maniatis, Meletios Athanasios Dimopoulos
Journal: Blood (2004)
SAT0452 Do Traditional Risk Factors for Knee Osteoarthritis Predict Pain Flares in Knee Osteoarthritis?: Table 1.
Authors: I. Atukorala, A. Pathmeswaran, T. Chang, Y. Zhang, D.J. Hunter
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Knee pain is the main cause of disability and reduced function in knee osteoarthritis (KOA). Though knee pain in osteoarthritis was previously perceived as a chronic condition it is now established that KOA pain fluctuates.There is emerging evidence that time variant risk factors-such as knee injury, buckling and mood- are associated with knee pain flares. But, it is not known whether conventional risk factors associated with KOA – age, gender, body mass index-are associated with pain flares in KOA. <h3>Objectives</h3> This study examines whether conventional time invariant risk factors for KOA and baseline pain felt by the patient are associated with KOA pain flares. <h3>Methods</h3> Study participants were selected from a 3-month web-based longitudinal follow up study developed to identify risk factors for KOA pain flares. Participants were requested to complete online questionnaire at days 0, 30, 60 and 90 (control period assessment points) and at time points whenever they experienced knee pain flare (case period assessment points) during the follow up period. A KOA pain flare was defined as current pain with a greater than 2 point increase (on a 0–10 point numeric rating scale) from the mildest KOA pain intensity reported at day 0. The association of pain flares with traditional risk factors for knee osteoarthritis -gender, weight, height, body mass index- was assessed by negative binomial regression. The duration of knee osteoarthritis, baseline pain intensity (lowest pain and highest pain scores at baseline) were similarly evaluated. The best explanatory variable was decided by forward selection. <h3>Results</h3> 345 persons (61.2% females) with multiple KOA pain flares were selected. Their mean age was 62.1years (SD ±8.2). The mean body mass index was 29.8kg/m<sup>2</sup> (SD ±6.5). The participants rated their baseline pain (on a numeric rating scale) as being 4.41 (SD± 2.02) and their worst pain as being 7.91 (SD ±1.74). An average of 1.92 (SD 2.59) flares were documented during the 3-month period. The levels of baseline pain – usual and worst pain felt at baseline- were the only parameters significantly associated with KOA pain flares (Table 1). <h3>Conclusions</h3> The baseline pain scores were the strongest predictors of pain flares of knee osteoarthritis. The traditional risk factors associated with knee osteoarthritis did not usefully predict pain flares. The traditional time invariant risk factors may not be associated with short term variability in pain though they are associated with long term outcomes of knee osteoarthritis. It is postulated that as knee pain is already present, time invariant risk factors that contributed to the original symptom causation are not associated with pain flare. <h3>Acknowledgement</h3> Joanna Makovey, Ben Metcalf, Lyn March and Kim Bennell <h3>Disclosure of Interest</h3> None declared
Democratic reforms and health: interpreting causal estimates – Authors' reply
Authors: Hannah Pieters, Daniele Curzi, Alessandro Olper, Johan Swinnen
Journal: The Lancet Global Health (2016)

In his Correspondence, Samuel Watson refers to two sets of African countries to support his argument that one cannot necessarily interpret the synthetic control method (SCM) results of our study1Pieters H Curzi D Olper A Swinnen J Effect of democratic reforms on child mortality: a synthetic control analysis.Lancet Glob Health. 2016; 4: 627-632Summary Full Text Full Text PDF PubMed Scopus (36) Google Scholar as causal effects. First, he presents SCM results for four countries (Mozambique, South Africa, Zambia, and Zimbabwe), which were not included in our study. These countries were not included in our SCM results because the SCM analysis for Mozambique and Zambia did not provide reliable SCM predictors (both had high Root Mean Square Predicted Error indicators), as was the case for several other countries (such as Nepal, Bangladesh, and Madagascar), for which SCM indicated strong reductions in child mortality following democratisation but which were dropped because of unreliable SCM predictors. Zimbabwe was not included because of its rather unique reverse political transformation to keep consistency in the analysis, and South Africa did not satisfy the standard criteria used to identify democratisation (ie, a switch in the Polity2 index). We do not want to speculate whether the reasons provided by Watson for the Mozambique and Zambia cases are correct since we excluded these countries because of unreliable predictors; but the graphs are consistent with our findings that there is on average a decline in child mortality following democratisation and that there is significant heterogeneity among countries (including no significant effect in a large part of the countries we analysed). Watson's second empirical argument based on a simple ad-hoc comparison of child mortality in a few African countries with and without democracy is puzzling because it is well known that a simple comparison of child mortality across countries does not allow to draw any causal conclusions since it does not control for various other factors that might play a role, which is precisely why we used an SCM approach. Finally, we welcome Watson's plea for better theoretical research, which can combine with improved empirical research to identify the causal mechanisms and actual effects of political reforms on health. We declare no competing interests. Democratic reform and health: interpreting causal estimatesIn The Lancet Global Health, Hannah Pieters and colleagues (September, 2016)1 analyse the effect of democratic reforms on child mortality across the world. We wish to highlight, however, that even with sophisticated causal inference techniques, such results cannot necessarily be interpreted as causal effects. Full-Text PDF Open Access
Weighing serological evidence of human exposure to animal influenza viruses − a literature review
Authors: Reina Saapke Sikkema, Gudrun Stephanie Freidl, Erwin de Bruin, Marion Koopmans
Journal: Eurosurveillance (2016)

Assessing influenza A virus strains circulating in animals and their potential to cross the species barrier and cause human infections is important to improve human influenza surveillance and preparedness. We reviewed studies describing serological evidence of human exposure to animal influenza viruses. Comparing serological data is difficult due to a lack of standardisation in study designs and in laboratory methods used in published reports. Therefore, we designed a scoring system to assess and weigh specificity of obtained serology results in the selected articles. Many studies report reliable evidence of antibodies to swine influenza viruses among persons occupationally exposed to pigs. Most avian influenza studies target H5, H7 and H9 subtypes and most serological evidence of human exposure to avian influenza viruses is reported for these subtypes. Avian influenza studies receiving a low grade in this review often reported higher seroprevalences in humans compared with studies with a high grade. Official surveillance systems mainly focus on avian H5 and H7 viruses. Swine influenza viruses and avian subtypes other than H5 and H7 (emphasising H9) should be additionally included in official surveillance systems. Surveillance efforts should also be directed towards understudied geographical areas, such as Africa and South America.
90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols.
Authors: Wojciech Jurczak, Agnieszka Giza, Dagmara Zimowska-Curylo, Alicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Wanda Knopinska-Posluszny, Andrzej Hellmann, Barbara Zdziarska, Tomasz Wrobel, Slawomira Krycz-Krzemien, Lidia Poplawska, Jan Walewski, Aleksander B. Skotnicki
Journal: Blood (2007)
GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab.
Authors: Thomas Friess, Christian Gerdes, Adam Nopora, Monika Patre, Susanne Preiss, Erwin van Puijenbroek, Christine Schuell, Sabine Bauer, Pablo Umana, Christian Klein
Journal: Blood (2007)
Glucose Metabolism After Gastric Banding and Gastric Bypass in Individuals With Type 2 Diabetes: Weight Loss Effect
Authors: Marlena M. Holter, Roxanne Dutia, Sarah M. Stano, Ronald L. Prigeon, Peter Homel, James J. McGinty, Scott J. Belsley, Christine J. Ren, Daniel Rosen, Blandine Laferrère
Journal: Diabetes Care (2016)

OBJECTIVE The superior effect of Roux-en-Y gastric bypass (RYGB) on glucose control compared with laparoscopic adjustable gastric banding (LAGB) is confounded by the greater weight loss after RYGB. We therefore examined the effect of these two surgeries on metabolic parameters matched on small and large amounts of weight loss. RESEARCH DESIGN AND METHODS Severely obese individuals with type 2 diabetes were tested for glucose metabolism, β-cell function, and insulin sensitivity after oral and intravenous glucose stimuli, before and 1 year after RYGB and LAGB, and at 10% and 20% weight loss after each surgery. RESULTS RYGB resulted in greater glucagon-like peptide 1 release and incretin effect, compared with LAGB, at any level of weight loss. RYGB decreased glucose levels (120 min and area under the curve for glucose) more than LAGB at 10% weight loss. However, the improvement in glucose metabolism, the rate of diabetes remission and use of diabetes medications, insulin sensitivity, and β-cell function were similar after the two types of surgery after 20% equivalent weight loss. CONCLUSIONS Although RYGB retained its unique effect on incretins, the superiority of the effect of RYGB over that of LAGB on glucose metabolism, which is apparent after 10% weight loss, was attenuated after larger weight loss.
Application of Nelarabine for Refractory or Relapsed T-Lymphatic Neoplasms In Adults Before Allogeneic Stem Cell Transplantation.
Authors: Evgeny Klyuchnikov, Nicolaus Kröger, Francis Ayuketang, Claudia Langebrake, Christine Wolschke, Heinrich Lellek, Axel R. Zander, Ulrike Bacher
Journal: Blood (2010)
Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.
Authors: Michael Craig, Wahid T Hanna, Fernando Cabanillas, Chien-Shing Chen, Sudha Parasuraman, Rachel Neuwirth, Owen A. O'Connor
Journal: Blood (2010)
Trajectory of Hemoglobin (Hb) in Patients Receiving Erythropoiesis-Stimulating Agents (ESAs) for Anemia Due to Concomitantly Administered Myelosuppressive Chemotherapy (CIA) (2006∼2008).
Authors: Jerrold Hill, Ze Cong, Gregory P. Hess, Robert Nordyke
Journal: Blood (2009)